Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Garadacimab in Subjects With Idiopathic Pulmonary Fibrosis
Conditions
Interventions
Garadacimab
Placebo
Locations
47
United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Pulmonary Associates Clinical Trials AZ
Phoenix, Arizona, United States
National Institute of Clinical Research
Huntington Beach, California, United States
University of Southern California - Center for Advanced Lung Disease
Los Angeles, California, United States
University of California Irvine
Orange, California, United States
Meris Clinical Research
Brandon, Florida, United States
Start Date
February 3, 2022
Primary Completion Date
January 2, 2024
Completion Date
January 2, 2024
Last Updated
December 13, 2024
NCT06238622
NCT07299695
NCT07466420
NCT06241560
NCT07407543
NCT05989698
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions